Kahn, Maria
Papukchieva, Steffeni
Jacyshyn-Owen, Elizabeth
Grimm, Stefan
Eberl, Markus
Schneeweiss, Sebastian http://orcid.org/0000-0003-2575-467X
Otten, Marina
Augustin, Matthias
Friedrich, Benjamin http://orcid.org/0000-0002-2198-9925
Article History
Received: 17 July 2023
Accepted: 29 August 2023
First Online: 14 September 2023
Declarations
:
: M.K., S.P., E.J.O., M.E. and B.F. are employed by the Temedica GmbH. M.O. does not have any conflicts of interests to declare. M.A. has served as a consultant, lecturer, researcher, and/or has received research grants from companies manufacturing drugs for chronic skin diseases, including AbbVie, ALK-Abelló, Almirall, Amgen, AOK Bundesverband, AOK BW, Bayer, Beiersdorf, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, BSN, Celgene, Centocor, DAK Gesundheit, Dermira, Desitin, Eli Lilly, Flen,Galderma, Genzyme, GlaxoSmithKline, Hexal, Incyte, Janssen, LEO Pharma, Medac, Menlo, Moelnlycke, MSD, Mylan, Novartis, Pfizer, Regeneron, Sandoz, Sanofi, Stallergenes, Trevi, and Urgo und XenoPort. S.G. has no conflict of interest. S. Schneeweis (ORCID# 0000-0003-2575-467X) is participating in investigator-initiated grants to the Brigham and Women’s Hospital from Boehringer Ingelheim and UCB unrelated to the topic of this study. He is a consultant to Aetion Inc., a software manufacturer of which he owns equity. His interests were declared, reviewed, and approved by the Brigham and Women’s Hospital in accordance with their institutional compliance policies.
: Ethical approval was not needed for our analysis since the data analysed here retrospectively is anonymized prescription sales data.